- Home
- PYPD vs ARTV Comparison
PYPD vs ARTV Comparison
Compare PYPD & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- ARTV
- Stock Information
- Founded
- PYPD 2008
- ARTV 2019
- Country
- PYPD Israel
- ARTV United States
- Employees
- PYPD N/A
- ARTV N/A
- Industry
- PYPD Medical/Dental Instruments
- ARTV
- Sector
- PYPD Health Care
- ARTV
- Exchange
- PYPD Nasdaq
- ARTV NYSE
- Market Cap
- PYPD 36.0M
- ARTV 39.0M
- IPO Year
- PYPD 2020
- ARTV 2024
- Fundamental
- Price
- PYPD $3.45
- ARTV $1.58
- Analyst Decision
- PYPD Strong Buy
- ARTV Strong Buy
- Analyst Count
- PYPD 5
- ARTV 8
- Target Price
- PYPD $11.40
- ARTV $18.14
- AVG Volume (30 Days)
- PYPD 1.4M
- ARTV 308.5K
- Earning Date
- PYPD 08-13-2025
- ARTV 08-28-2025
- Dividend Yield
- PYPD N/A
- ARTV N/A
- EPS Growth
- PYPD N/A
- ARTV N/A
- EPS
- PYPD N/A
- ARTV N/A
- Revenue
- PYPD N/A
- ARTV N/A
- Revenue This Year
- PYPD N/A
- ARTV N/A
- Revenue Next Year
- PYPD N/A
- ARTV N/A
- P/E Ratio
- PYPD N/A
- ARTV N/A
- Revenue Growth
- PYPD N/A
- ARTV N/A
- 52 Week Low
- PYPD $2.30
- ARTV $1.47
- 52 Week High
- PYPD $4.42
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- PYPD 53.89
- ARTV N/A
- Support Level
- PYPD $3.42
- ARTV N/A
- Resistance Level
- PYPD $3.57
- ARTV N/A
- Average True Range (ATR)
- PYPD 0.18
- ARTV 0.00
- MACD
- PYPD -0.03
- ARTV 0.00
- Stochastic Oscillator
- PYPD 52.55
- ARTV 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).